Status:
COMPLETED
Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt
Lead Sponsor:
Alexandria University
Conditions:
Covid19
Eligibility:
All Genders
12-90 years
Phase:
PHASE4
Brief Summary
Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis. By comparing the positive-stranded RNA genomes of HCV and SA...
Eligibility Criteria
Inclusion
- mild- moderate COVID-19 confirmed by PCR
Exclusion
- Patients on renal dialysis
- Severe COVID-19 cases
- Patients on amiodarone therapy (given the reported FDA warning of an interaction between amiodarone and sofosbuvir that might lead to severe bradycardia).
- Children \< 12 years
- Pregnant and breast feeding women
- Exacerbation of hepatitis B
Key Trial Info
Start Date :
November 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 12 2020
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04773756
Start Date
November 1 2020
End Date
December 12 2020
Last Update
February 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amr Aly Abd elmoety
Alexandria, Egypt, 21521